| Advertisement |
 |
news roundup
Who has moved companies and what milestones are companies reporting this month? In this mid-month update, we hear from: KCR, AiCure, Advanced Clinical, CluePoints, Signant Health, TrialScope, Kayentis and more.
MarkLogic, a data platform provider and eyeforpharma, released a report “Defragmenting Data for the Future of Pharma R&D,” which found that only 2% of pharmaceutical executives consider their current levels of data sharing effective in bringing about critical innovation.
|
|
|
advertisement
Anti-Microbial Resistance and the Role of Vaccines
Europe: Thursday, November 14, 2019 at 3pm GMT | 4pm CET
North America: Thursday, November 21, 2019 at 11am EST | 10am CST | 8am PST
 Register Now
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Certara announced the availability of PK Submit, a technology solution for automating the creation of PK CDISC domains during Non-Compartmental Analysis. The FDA and PMDA both require that CDISC study data standards be applied to preclinical and clinical data submitted electronically as part of NDA.
|
advertisement
Trends and Insights for Your Oncology Trial
Tuesday, November 12, 2019 at 10am EST
 Register Now
|
Articles
A recent executive gathering tackled clinical operations issues. This article summarizes their key points of discussion.
The Parkinson’s Progression Markers Initiative (PPMI) study launched in 2010 sponsored by the Michael J. Fox Foundation. It aims to find reliable and consistent biomarkers for PD progression by studying cohorts of Parkinson’s, populations at risk for PD, and controls without PD. Participants in PPMI commit to long-term participation, providing biospecimens (e.g., blood, urine, spinal fluid), and undergoing multiple neuroimaging, clinical and behavioral procedures, and assessments over a period of at least five years.
|
advertisement
Launching Medical Devices in the Japanese Market
How to navigate regulatory and reimbursement approval
 On Demand
|
|
|
|
|
advertisement
Will Decentralized Clinical Trials Compound Patient and Data Quality Risks?
 On Demand
|
Blog Posts
The “Provocative Ideas” presented by The Avoca Group’s COO Dennis Salotti in a recent article include the need to study generational cohorts, and that many professionals travel seamlessly between CROs and pharma.
| |
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
